Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential

  • Rodríguez Fernández, Silvia
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Aguilera, Eva|||0000-0002-0164-4006
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Vázquez, Federico|||0000-0001-6493-2374
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to autoimmunity. Countless factors can potentially impact on the proper functionality of the DCs, which range from altered subset distribution, impaired phagocytic function to abnormal gene expression. Moreover, in T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D clinical course is likely to be more aggressive in children and adolescents and entails severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations in pediatric T1D at different stages, as well as to characterize their phagocytosis ability and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D, with established disease and control subjects were recruited. Firstly, DCs subsets from peripheral blood were found quantitatively altered during the first year of disease, but recovered in the second year of progression. Secondly, to study the tolerogenic functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic apoptotic beta cells, which are able to induce tolerance, as previously demonstrated by our group in DCs from adult patients with T1D. In this study, monocyte-derived DCs from pediatric patients with T1D and control subjects were assessed in terms of PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less efficiently than DCs from control subjects, inversely correlating with disease evolution. Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine profile, and membrane expression of immunological markers in DCs was consistent with tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs phagocytosis, although tolerance induction could still function optimally. Therefore, this study provides useful data for patient follow-up and stratification in immunotherapy clinical trials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Partial remission and early stages of pediatric type 1 diabetes display immunoregulatory changes. A pilot study

  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Fonolleda, Mireia
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Raina, María Belén
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Planas, Raquel
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that results from β-cell destruction. The onset of the disease, which arises after a long asymptomatic period of autoimmune attack, may be followed by a relapsing and remitting progression, a phenomenon that is most evident during the partial remission phase (PR). This stage lasts for a few months, shows minor requirements of exogenous insulin and could be explained by a recovery of immunological tolerance. This study aims to identify new biomarkers at early stages of pediatric T1D that reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52) and age-related control subjects (n = 30) were recruited. Immune response-related molecules and lymphocyte subsets were determined starting at T1D onset and until the second year of progression. Results showed that circulating TGF-β levels decreased during PR, and that betatrophin concentration was increased in all the considered stages without differing among studied checkpoints. Moreover, an increase of regulatory T, B and NK subsets was found during T1D progression, probably reflecting an attempt to restore self-tolerance. By contrast, a reduction in monocyte levels was observed at the early stages of diabetes. The results reveal significant changes in immunological parameters during the different early stages of T1D in children, which could ultimately serve as potential biomarkers to characterize the progression of T1D.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Vázquez, Federico|||0000-0001-6493-2374
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes (T1D) is a chronic metabolic disease characterized by the autoimmune destruction of β-cells in the pancreatic islets. T1D is preceded by islet-specific inflammation led by several immune cells. Among them, natural killer (NK) cells are emerging as important players in T1D development. Human NK cells are characterized by CD56 and CD16 expression, which allows classifying NK cells into four subsets: 1) CD56 dim CD16 + or effector NK cells (NK); 2) CD56 bright CD16 - or regulatory NK cells (NK); 3) intermediate CD56 bright CD16 + NK cells; and 4) CD56 dim CD16 - NK cells, whose function is not well determined. Since many studies have shown that T1D progression is associated with changes in various immune cell types, we hypothesize that the kinetics of NK cell subsets in the blood could correlate with different stages of T1D. To that aim, pediatric patients newly diagnosed with T1D were recruited, and peripheral NK cell subsets were analyzed by flow cytometry at several disease checkpoints: disease onset, partial remission (PR), 8 months (for non-remitters), and 12 months of progression. Our results showed that total NK cells and their four subsets are altered at the early stages of T1D. A decrease in the counts and percentage of total NK cells and NK cells at the different disease stages was found when compared to controls. These results suggest the extravasation of these cells into the islets at disease onset, which is maintained throughout the follow-up. By contrast, NK cells increased during the early stages after T1D onset, and both intermediate NK cells and CD56 dim CD16 - NK cells diminished at the PR stage, which might reflect the immunoregulatory attempts and could be candidate biomarkers for this stage. Also, CD56 dim CD16 - NK cells increased during T1D progression. Finally, changes in CD16 expression were identified in the different T1D stages, highlighting a CD16 expression reduction in total NK cells and NK cells 1 year after diagnosis. That may reflect a state of exhaustion after multiple cell-to-cell interactions. Altogether, our preliminary data provide a longitudinal picture of peripheral NK cell subpopulations during the different T1D stages, which could be potential candidate biomarkers indicators of disease progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Caroz-Armayones, Josep M.
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Valls, Aina|||0000-0002-0751-5029
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Castaño, Luis|||0000-0003-0437-9401
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
The partial remission (PR) phase, a period experienced by most patients with type 1 diabetes (T1D) soon after diagnosis, is characterized by low insulin requirements and improved glycemic control. Given the great potential of this phase as a therapeutic window for immunotherapies because of its association with immunoregulatory mechanisms and β-cell protection, our objective was to find peripheral immunological biomarkers for its better characterization, monitoring, and prediction. The longitudinal follow-up of 17 pediatric patients with new-onset T1D over one year revealed that, during the PR phase, remitter patients show increased percentages of effector memory (EM) T lymphocytes, terminally differentiated EM T lymphocytes, and neutrophils in comparison to non-remitter patients. On the contrary, remitter patients showed lower percentages of naïve T lymphocytes, regulatory T cells (T), and dendritic cells (DCs). After a year of follow-up, these patients also presented increased levels of regulatory B cells and transitional T1 B lymphocytes. On the other hand, although none of the analyzed cytokines (IL-2, IL-6, TGF-β1, IL-17A, and IL-10) could distinguish or predict remission, IL-17A was increased at T1D diagnosis in comparison to control subjects, and remitter patients tended to maintain lower levels of this cytokine than non-remitters. Therefore, these potential monitoring immunological biomarkers of PR support that this stage is governed by both metabolic and immunological factors and suggest immunoregulatory attempts during this phase. Furthermore, since the percentage of T, monocytes, and DCs, and the total daily insulin dose at diagnosis were found to be predictors of the PR phase, we next created an index-based predictive model comprising those immune cell percentages that could potentially predict remission at T1D onset. Although our preliminary study needs further validation, these candidate biomarkers could be useful for the immunological characterization of the PR phase, the stratification of patients with better disease prognosis, and a more personalized therapeutic management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunoregulatory Biomarkers of the Remission Phase in Type 1 Diabetes, miR-30d-5p Modulates PD-1 Expression and Regulatory T Cell Expansion

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Armengol, Maria Pilar
  • Alcalde-Herraiz, Marta|||0009-0002-4405-1814
  • Català, Martí|||0000-0003-3308-9905
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Sunye, Sergi
  • Valls, Aina|||0000-0002-0751-5029
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Vives Pi, Marta|||0000-0003-3735-0779
The partial remission (PR) phase of type 1 diabetes (T1D) is an underexplored period characterized by endogenous insulin production and downmodulated autoimmunity. To comprehend the mechanisms behind this transitory phase and develop precision medicine strategies, biomarker discovery and patient stratification are unmet needs. MicroRNAs (miRNAs) are small RNA molecules that negatively regulate gene expression and modulate several biological processes, functioning as biomarkers for many diseases. Here, we identify and validate a unique miRNA signature during PR in pediatric patients with T1D by employing small RNA sequencing and RT-qPCR. These miRNAs were mainly related to the immune system, metabolism, stress, and apoptosis pathways. The implication in autoimmunity of the most dysregulated miRNA, miR-30d-5p, was evaluated in vivo in the non-obese diabetic mouse. MiR-30d-5p inhibition resulted in increased regulatory T cell percentages in the pancreatic lymph nodes together with a higher expression of CD200. In the spleen, a decrease in PD-1 + T lymphocytes and reduced PDCD1 expression were observed. Moreover, miR-30d-5p inhibition led to an increased islet leukocytic infiltrate and changes in both effector and memory T lymphocytes. In conclusion, the miRNA signature found during PR shows new putative biomarkers and highlights the immunomodulatory role of miR-30d-5p, elucidating the processes driving this phase.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Corrigendum, NK cell subsets changes in partial remission and early stages of pediatric type 1 diabetes(Front Immunol., 11, (611522), 10.3389/fimmu.2020.611522)

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Vázquez, Federico|||0000-0001-6493-2374
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
In the published article, there was an error in the Funding statement. The Funding statement was displayed as "This work has been funded by the Spanish Government (FIS PI18/00436) co-financed with the European Regional Development funds (FEDER), and by DiabetesCero Foundation.". The correct Funding statement appears below. This study has been funded by Instituto de Salud Carlos III through the project PI18/00436 (Co-funded by European Regional Development Fund 'A way to make Europe'), and by DiabetesCero Foundation. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Corrigendum, Candidate biomarkers for the prediction and monitoring of partial remission in pediatric type 1 diabetes(Front. Immunol., (2022), 13, (825426), 10.3389/fimmu.2022.825426)

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Caroz-Armayones, Josep M.
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Valls, Aina|||0000-0002-0751-5029
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Castaño, Luis|||0000-0003-0437-9401
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
In the published article, there was an error in the Funding statement. One of the funding bodies was incorrectly listed as "the Spanish Government (FIS PI18/00436)". The correct Funding statement appears below.